3 Stocks Advancing The Health Care Sector

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 37 points (0.2%) at 17,115 as of Thursday, Sept. 4, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,639 issues advancing vs. 1,333 declining with 167 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is up 0.2%. Top gainers within the sector include WellPoint ( WLP), up 1.6%, Cigna ( CI), up 1.3%, Aetna ( AET), up 0.9%, UnitedHealth Group ( UNH), up 0.9% and Thermo Fisher Scientific ( TMO), up 0.6%. On the negative front, top decliners within the sector include Universal Health Services ( UHS), down 4.4%, Jazz Pharmaceuticals ( JAZZ), down 3.6%, Tenet Healthcare ( THC), down 3.5%, Biomarin Pharmaceutical ( BMRN), down 2.8% and Novo Nordisk A/S ( NVO), down 2.0%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Humana ( HUM) is one of the companies pushing the Health Care sector higher today. As of noon trading, Humana is up $1.04 (0.8%) to $128.29 on heavy volume. Thus far, 812,560 shares of Humana exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $127.33-$129.75 after having opened the day at $127.35 as compared to the previous trading day's close of $127.25.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Humana Inc., a health care company, offers a range of insurance products, and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in Retail, Employer Group, Healthcare Services, and Other Businesses segments. Humana has a market cap of $19.7 billion and is part of the health services industry. Shares are up 23.3% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts who rate Humana a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Humana Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Illumina ( ILMN) is up $1.83 (1.0%) to $179.61 on light volume. Thus far, 329,094 shares of Illumina exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $177.81-$182.27 after having opened the day at $182.27 as compared to the previous trading day's close of $177.78.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. Illumina has a market cap of $25.1 billion and is part of the drugs industry. Shares are up 60.8% year-to-date as of the close of trading on Wednesday. Currently there are 9 analysts who rate Illumina a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and compelling growth in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Illumina Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Actavis ( ACT) is up $1.86 (0.8%) to $230.41 on average volume. Thus far, 932,461 shares of Actavis exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $228.55-$232.39 after having opened the day at $229.70 as compared to the previous trading day's close of $228.55.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Actavis has a market cap of $60.5 billion and is part of the drugs industry. Shares are up 36.0% year-to-date as of the close of trading on Wednesday. Currently there are 16 analysts who rate Actavis a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Actavis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Canopy Growth Lets Down Eager Pot Investors; PayPal Keeps Dominating -- ICYMI

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Dow, S&P 500 and Nasdaq Tumble After Trump Calls Off North Korea Summit

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers